<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="74974eef-499f-456f-8683-da23bb0c1137"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use COLCHICINE TABLETS safely and effectively. See full prescribing information for COLCHICINE TABLETS. </content>
      <content styleCode="bold">Â <br/>
         <br/>
      </content>
      <content styleCode="bold">COLCHICINE tablets, for oral use <br/>
      </content>
      <content styleCode="bold">Initial U.S. Approval: 1961 </content>
   </title>
   <effectiveTime value="20250327"/>
   <setId root="7daef7e2-888d-4116-81a9-2c02b9ef97ef"/>
   <versionNumber value="18"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals of New York, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-710" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-710" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-710" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-710" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ce108e69-a4d4-4b94-95e4-5092bb8b153b"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250327"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="65162-710" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Colchicine</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Colchicine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.6"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SML2Y3J35T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COLCHICINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="SML2Y3J35T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>COLCHICINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYDEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="65162-710-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="65162-710-09" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="65162-710-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA204711" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A10</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_e5b9f610-d11e-48ce-9a4e-3d4faa0bf500">
               <id root="3bb6382f-c01d-45cd-8c75-b37eaad47cdb"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1Â  INDICATIONS AND USAGE </content>
               </title>
               <text/>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Colchicine tablets, USP are an alkaloid indicated for: </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Prophylaxis and treatment of gout flares in adults (<linkHtml href="#LINK_656cedb8-e671-4b2d-a49c-9281f8c13136">1.1</linkHtml>).</item>
                           <item>Familial Mediterranean fever (FMF) in adults and children 4 years or older <linkHtml href="#LINK_c48c37d4-c40e-4e28-a6e8-d81cc21382e8">(1.2)</linkHtml>. 
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_656cedb8-e671-4b2d-a49c-9281f8c13136">
                     <id root="f9f5fa06-9b4b-40f7-92e0-d28f2cfe2e85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Gout Flares</title>
                     <text>
                        <paragraph>Colchicine tablets, USP are indicated for prophylaxis and the treatment of acute gout flares. </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline">Prophylaxis of Gout Flares: </content>
                           </item>
                        </list>
                        <paragraph>Colchicine tablets, USP are indicated for prophylaxis of gout flares. </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline">Treatment of Gout Flares: </content>
                           </item>
                        </list>
                        <paragraph>Colchicine tablets, USP are indicated for treatment of acute gout flares when taken at the first sign of a flare.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c48c37d4-c40e-4e28-a6e8-d81cc21382e8">
                     <id root="23a09001-6cdb-474f-bda8-a30562d8576f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Familial Mediterranean Fever (FMF)</title>
                     <text>
                        <paragraph>Colchicine tablets, USP are indicated in adults and children four years or older for treatment of familial Mediterranean fever (FMF). </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_101411fa-4482-4da1-aed8-19c6f57d3e28">
               <id root="23d4875e-eca1-474c-9309-ea6eb79c179f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2Â  DOSAGE AND ADMINISTRATION </content>
               </title>
               <text>
                  <paragraph>The long-term use of colchicine, USP is established for FMF and the prophylaxis of gout flares, but the safety and efficacy of repeat treatment for gout flares has not been evaluated. The dosing regimens for colchicine tablets, USP are different for each indication and must be individualized. </paragraph>
                  <paragraph>The recommended dosage of colchicine tablets, USP depends on the patientâs age, renal function, hepatic function and use of co-administered drugs<content styleCode="italics"> [see <linkHtml href="#www.splportal.comLINK_46b96977-a66c-4790-bdb2-a0f65ed76028">Dosage and Administration (2.4</linkHtml>, <linkHtml href="#www.splportal.comLINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">2.5</linkHtml>, <linkHtml href="#www.splportal.comLINK_1bffeea6-d605-419b-8747-dc2ce6e7d2ab">2.6</linkHtml>)]</content>
                     <content styleCode="italics">. </content>
                  </paragraph>
                  <paragraph>Colchicine tablets, USP are administered orally without regard to meals.</paragraph>
                  <paragraph>Colchicine tablets, USP are not an analgesic medication and should not be used to treat pain from other causes.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="bold">Gout Flares:</content>
                              </content>
                              <br/>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Prophylaxis of Gout Flares:</content> 0.6 mg once or twice daily in adults and adolescents older than 16 years of age (<linkHtml href="#LINK_bb352476-6710-496d-b80b-76dcf2246150">2.1</linkHtml>). Maximum dose 1.2 mg/day. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Treatment of Gout Flares:</content> 1.2 mg (two tablets) at the first sign of a gout flare followed by 0.6 mg (one tablet) one hour later (<linkHtml href="#LINK_bb352476-6710-496d-b80b-76dcf2246150">2.1</linkHtml>).</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold">FMF:</content> Adults and children older than 12 years 1.2 to 2.4 mg; children 6 to 12 years 0.9 to 1.8 mg; children 4 to 6 years 0.3 to 1.8 mgÂ <linkHtml href="#LINK_0089e1d9-cfc4-4610-98e4-19c70cce4581">(2.2,</linkHtml>Â <linkHtml href="#LINK_8fb2ea19-1b8d-4bbd-bbed-f1ea7bb0340d">2.3)</linkHtml>. <list listType="unordered" styleCode="Circle">
                                 <item>Give total daily dose in one or two divided doses <linkHtml href="#LINK_0089e1d9-cfc4-4610-98e4-19c70cce4581">(2.2)</linkHtml>. 
</item>
                                 <item>Increase or decrease the dose as indicated and as tolerated in increments of 0.3 mg/day, not to exceed the maximum recommended daily dose <linkHtml href="#LINK_0089e1d9-cfc4-4610-98e4-19c70cce4581">(2.2)</linkHtml>. </item>
                              </list>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Disk">
                           <item>Colchicine tablets, USP are administered orally without regard to meals.</item>
                           <item>See full prescribing information (FPI) for dose adjustment regarding patients with impaired renal function <linkHtml href="#LINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">(2.5)</linkHtml>, impaired hepatic function <linkHtml href="#LINK_1bffeea6-d605-419b-8747-dc2ce6e7d2ab">(2.6)</linkHtml>, the patientâs ageÂ <linkHtml href="#LINK_8fb2ea19-1b8d-4bbd-bbed-f1ea7bb0340d">(2.3,</linkHtml>Â <linkHtml href="#LINK_17a72a91-341e-44f1-ae76-3f20a780e620">8.5)</linkHtml>Â or use of co-administered drugs <linkHtml href="#LINK_46b96977-a66c-4790-bdb2-a0f65ed76028">(2.4)</linkHtml>. </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_bb352476-6710-496d-b80b-76dcf2246150">
                     <id root="3460455b-a4ba-486e-ae9b-0c989ce35e74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Gout Flares</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Prophylaxis of Gout Flares </content>
                        </paragraph>
                        <paragraph>The recommended dosage of colchicine tablets, USP for prophylaxis of gout flares for adults and adolescents older than 16 years of age is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of gout flares is 1.2 mg/day. </paragraph>
                        <paragraph>An increase in gout flares may occur after initiation of uric acid-lowering therapy, including pegloticase, febuxostat and allopurinol, due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. Colchicine tablets, USP are recommended upon initiation of gout flare prophylaxis with uric acid-lowering therapy. Prophylactic therapy may be beneficial for at least the first six months of uric acid-lowering therapy. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Treatment of Gout Flares </content>
                        </paragraph>
                        <paragraph>The recommended dose of colchicine tablets, USP for treatment of a gout flare is 1.2 mg (two tablets) at the first sign of the flare followed by 0.6 mg (one tablet) one hour later. Higher doses have not been found to be more effective. The maximum recommended dose for treatment of gout flares is 1.8 mg over a 1-hour period. Colchicine tablets, USP may be administered for treatment of a gout flare during prophylaxis at doses not to exceed 1.2 mg (two tablets) at the first sign of the flare followed by 0.6 mg (one tablet) one hour later. Wait 12 hours and then resume the prophylactic dose.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0089e1d9-cfc4-4610-98e4-19c70cce4581">
                     <id root="c478d44a-e153-4081-b6b7-4bb882f25218"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 FMF</title>
                     <text>
                        <paragraph>The recommended dosage of colchicine tablets, USP for FMF in adults is 1.2 mg to 2.4 mg daily. </paragraph>
                        <paragraph>Colchicine tablets, USP should be increased as needed to control disease and as tolerated in increments of 0.3 mg/day to a maximum recommended daily dose. If intolerable side effects develop, the dose should be decreased in increments of 0.3 mg/day. The total daily colchicine tablets, USP dose may be administered in one to two divided doses. </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8fb2ea19-1b8d-4bbd-bbed-f1ea7bb0340d">
                     <id root="a1fda736-9de3-4cc5-8632-8c085b73d7b5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Pediatric Dosage</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Prophylaxis and Treatment of Gout Flares </content>
                        </paragraph>
                        <paragraph>Colchicine tablets, USP are not recommended for pediatric use in prophylaxis or treatment of gout flares.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FMF</content>
                        </paragraph>
                        <paragraph>The recommended dosage of colchicine tablets, USP for FMF in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily: </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Children 4 to 6 years: 0.3 mg to 1.8 mg daily 
</item>
                           <item>Children 6 to 12 years: 0.9 mg to 1.8 mg daily 
</item>
                           <item>Adolescents older than 12 years: 1.2 mg to 2.4 mg daily </item>
                        </list>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_46b96977-a66c-4790-bdb2-a0f65ed76028">
                     <id root="37a48951-bc44-4f14-a377-f36eceb754da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dose Modification for Co-administration of Interacting Drugs</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Concomitant Therapy </content>
                        </paragraph>
                        <paragraph>Co-administration of colchicine tablets, USP with drugs known to inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of colchicine-induced toxic effects <content styleCode="italics">(Table 1)</content>. If patients are taking or have recently completed treatment with drugs listed in <content styleCode="italics">Table 1</content> within the prior 14 days, the dose adjustments are as shown in the table below <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1. Colchicine Tablets, USP Dose Adjustment for Co-administration with Interacting Drugs if No Alternative Available</content>
                           <content styleCode="bold">
                              <sup>*</sup>
                           </content>
                        </paragraph>
                        <table width="100%" cellspacing="0" cellpadding="0" border="1">
                           <col width="17pt"/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="8" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Strong CYP3A4 Inhibitors<sup>â </sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Noted or Anticipated</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Outcome</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">FMF</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Prophylaxis of Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Treatment of Gout Flares</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Intended Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Intended Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Intended</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Atazanavir</paragraph>
                                    <paragraph>Clarithromycin</paragraph>
                                    <paragraph>Darunavir/</paragraph>
                                    <paragraph>Ritonavir<sup>â¡</sup>
                                    </paragraph>
                                    <paragraph>Indinavir</paragraph>
                                    <paragraph>Itraconazole</paragraph>
                                    <paragraph>Ketoconazole</paragraph>
                                    <paragraph>Lopinavir/</paragraph>
                                    <paragraph>Ritonavir<sup>â¡</sup>
                                    </paragraph>
                                    <paragraph>Nefazodone</paragraph>
                                    <paragraph>Nelfinavir</paragraph>
                                    <paragraph>Ritonavir</paragraph>
                                    <paragraph>Saquinavir</paragraph>
                                    <paragraph>Telithromycin</paragraph>
                                    <paragraph>Tipranavir/</paragraph>
                                    <paragraph>Ritonavir<sup>â¡</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Significant increase in colchicine, USP plasma levels<sup>*</sup>; fatal colchicine, USP toxicity has been reported with clarithromycin, a strong CYP3A4 inhibitor.</paragraph>
                                    <paragraph>Similarly, significant increase in colchicine, USP plasma levels is anticipated with other strong CYP3A4 inhibitors.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.2 mg (2 tablets) followed by 0.6 mg (1 tablet) 1 hour later. </paragraph>
                                    <paragraph>Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. </paragraph>
                                    <paragraph>Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose of 1.2 to 2.4 mg </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum</paragraph>
                                    <paragraph>daily dose of 0.6 mg (may be given as 0.3 mg twice a day) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Moderate CYP3A4 Inhibitors</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Noted or Anticipated</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Outcome</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">FMF</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Prophylaxis of Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Treatment of Gout Flares</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Intended Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Intended Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Intended</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Amprenavir<sup>â¡</sup>
                                    </paragraph>
                                    <paragraph>Aprepitant</paragraph>
                                    <paragraph>Diltiazem</paragraph>
                                    <paragraph>Erythromycin</paragraph>
                                    <paragraph>Fluconazole</paragraph>
                                    <paragraph>Fosamprenavir<sup>â¡</sup>
                                    </paragraph>
                                    <paragraph>(prodrug of</paragraph>
                                    <paragraph>Amprenavir)</paragraph>
                                    <paragraph>Grapefruit juice</paragraph>
                                    <paragraph>Verapamil</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Significant increase in colchicine, USP plasma concentration is anticipated.</paragraph>
                                    <paragraph>Neuromuscular toxicity has been reported with diltiazem and verapamil interactions.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg twice a day or 0.6 mg once a day</paragraph>
                                    <paragraph>0.3 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.2 mg (2 tablets) followed by 0.6 mg (1 tablet) 1 hour later.</paragraph>
                                    <paragraph>Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.2 mg (2 tablets) x 1 dose. </paragraph>
                                    <paragraph>Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum</paragraph>
                                    <paragraph>daily dose of 1.2 to 2.4 mg</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice a day) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">P-gp Inhibitors<sup>â </sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Noted or Anticipated</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Outcome</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                                    <br/>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">FMF</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Prophylaxis of Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Treatment of Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Intended Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Intended Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Intended</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosage</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Cyclosporine</paragraph>
                                    <paragraph>Ranolazine</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Significant increase in colchicine, USP plasma levels<sup>*</sup>; fatal colchicine, USP toxicity has been reported with cyclosporine, a P-gp inhibitor. </paragraph>
                                    <paragraph>Similarly,</paragraph>
                                    <paragraph>significant increase in colchicine, USP plasma levels is anticipated with other P-gp inhibitors. </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.2 mg (2 tablets) followed by 0.6 mg (1 tablet) 1 hour later.</paragraph>
                                    <paragraph>Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose. </paragraph>
                                    <paragraph>Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose of 1.2 to 2.4 mg </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum<br/> daily dose of 0.6 mg (may be given as 0.3 mg twice a day) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <sup>*</sup> For magnitude of effect on colchicine, USP plasma concentrations <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>]</content>
                                    </paragraph>
                                    <paragraph>
                                       <sup>â </sup> Patients with renal or hepatic impairment should not be given colchicine tablets, USP in conjunction with strong CYP3A4 or P-gp inhibitors <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_dcd2ff28-8d01-42d3-a3a2-2b3b768408b1">Contraindications (4)</linkHtml>].</content>
                                    </paragraph>
                                    <paragraph>
                                       <sup>â¡</sup> When used in combination with Ritonavir, see dosing recommendations for strong CYP3A4 inhibitors <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_dcd2ff28-8d01-42d3-a3a2-2b3b768408b1">Contraindications (4)</linkHtml>].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Table 2. Colchicine Tablets, USP Dose Adjustment for Co-administration with Protease Inhibitors</content>
                        </paragraph>
                        <table width="100%" cellspacing="0" cellpadding="0" border="1">
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Protease Inhibitor</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Clinical Comment</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">w/Colchicine - Prophylaxis </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">of Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">w/Colchicine â</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Treatment of Gout Flares</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">w/Colchicine â</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Treatment of FMF</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Atazanavir sulfate</paragraph>
                                    <paragraph>(Reyataz)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal or hepatic impairment should not be given colchicine, USP with Reyataz.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Darunavir (Prezista)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal or hepatic impairment should not be given colchicine, USP with Prezista/ritonavir.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Fosamprenavir</paragraph>
                                    <paragraph>(Lexiva) with Ritonavir</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal</paragraph>
                                    <paragraph>or hepatic</paragraph>
                                    <paragraph>impairment should</paragraph>
                                    <paragraph>not be given</paragraph>
                                    <paragraph>colchicine, USP </paragraph>
                                    <paragraph>with </paragraph>
                                    <paragraph>Lexiva/ritonavir.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose</paragraph>
                                    <paragraph>of 0.6 mg (may be</paragraph>
                                    <paragraph>given as 0.3 mg twice</paragraph>
                                    <paragraph>a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Fosamprenavir</paragraph>
                                    <paragraph>(Lexiva)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal</paragraph>
                                    <paragraph>or hepatic</paragraph>
                                    <paragraph>impairment should</paragraph>
                                    <paragraph>not be given</paragraph>
                                    <paragraph>colchicine, USP </paragraph>
                                    <paragraph>with</paragraph>
                                    <paragraph>Lexiva/ritonavir.</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.2 mg (2 tablets) x 1 dose. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose</paragraph>
                                    <paragraph>of 1.2 mg (may be</paragraph>
                                    <paragraph>given as 0.6 mg twice</paragraph>
                                    <paragraph>a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg twice a day or 0.6 mg once a day</paragraph>
                                    <paragraph>0.3 mg once a day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Indinavir (Crixivan)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal</paragraph>
                                    <paragraph>or hepatic</paragraph>
                                    <paragraph>impairment should</paragraph>
                                    <paragraph>not be given</paragraph>
                                    <paragraph>colchicine, USP </paragraph>
                                    <paragraph>with Crixivan</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose</paragraph>
                                    <paragraph>of 0.6 mg (may be</paragraph>
                                    <paragraph>given as 0.3 mg twice</paragraph>
                                    <paragraph>a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Lopinavir/Ritonavir<br/> (Kaletra)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal<br/> or hepatic<br/> impairment should<br/> not be given<br/> colchicine, USP <br/> with Kaletra</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose<br/> of 0.6 mg (may be<br/> given as 0.3 mg twice<br/> a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nelfinavir mesylate</paragraph>
                                    <paragraph>(Viracept)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal</paragraph>
                                    <paragraph>or hepatic</paragraph>
                                    <paragraph>impairment should</paragraph>
                                    <paragraph>not be given</paragraph>
                                    <paragraph>colchicine, USP </paragraph>
                                    <paragraph>with Viracept</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose</paragraph>
                                    <paragraph>of 0.6 mg (may be</paragraph>
                                    <paragraph>given as 0.3 mg twice</paragraph>
                                    <paragraph>a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Ritonavir (Norvir)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal</paragraph>
                                    <paragraph>or hepatic</paragraph>
                                    <paragraph>impairment should</paragraph>
                                    <paragraph>not be given</paragraph>
                                    <paragraph>colchicine, USP </paragraph>
                                    <paragraph>with Norvir</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose</paragraph>
                                    <paragraph>of 0.6 mg (may be</paragraph>
                                    <paragraph>given as 0.3 mg twice</paragraph>
                                    <paragraph>a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Saquinavir mesylate</paragraph>
                                    <paragraph>(Invirase)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal or hepatic</paragraph>
                                    <paragraph>impairment should not be given colchicine, USP with Invirase/ritonavir</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Tipranavir (Aptivus)</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Patients with renal or hepatic</paragraph>
                                    <paragraph>impairment should not be given colchicine, USP with</paragraph>
                                    <paragraph>Aptivus/ritonavir</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Original Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adjusted Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.6 mg twice a day</paragraph>
                                    <paragraph>0.6 mg once a day</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0.3 mg once a day</paragraph>
                                    <paragraph>0.3 mg once every other day</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Treatment of gout flares with colchicine tablets, USP is not recommended in patients receiving prophylactic dose of colchicine tablets, USP and CYP3A4 inhibitors.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">
                     <id root="bbb5b3a3-be3c-4530-ad16-aa4bc6de1381"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dose Modification in Renal Impairment</title>
                     <text>
                        <paragraph>Colchicine, USP dosing must be individualized according to the patient's renal function<content styleCode="italics"> [see </content>Â <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">Use in Specific Populations (8.6)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>Cl<sub>cr</sub> in mL/minute may be estimated from serum creatinine (mg/dL) determination using the following formula: </paragraph>
                        <paragraph>Â Â Â Â Â Â Â Â Â Â Â  [140-age (years) Ã weight (kg)] </paragraph>
                        <paragraph>Cl<sub>cr</sub> = ---------------------------------------- Ã 0.85 for female patients </paragraph>
                        <paragraph>Â Â Â Â Â Â Â Â Â Â Â Â  72 Ã serum creatinine (mg/dL) </paragraph>
                        <paragraph>
                           <content styleCode="bold">Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gout Flares </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Prophylaxis of Gout Flares </content>
                        </paragraph>
                        <paragraph>For prophylaxis of gout flares in patients with mild (estimated creatinine clearance [Cl<sub>cr</sub>] 50 to 80 mL/min) to moderate (Cl<sub>cr</sub> 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg/day and any increase in dose should be done with close monitoring. For the prophylaxis of gout flares in patients undergoing dialysis, the starting doses should be 0.3 mg given twice a week with close monitoring<content styleCode="italics"> [see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>,</content>
                           <content styleCode="italics">
                              <linkHtml href="#www.splportal.comLINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9"> Use in Specific Populations (8.6)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Treatment of Gout Flares </content>
                        </paragraph>
                        <paragraph>For treatment of gout flares in patients with mild (Cl<sub>cr</sub> 50 to 80 mL/min) to moderate (Cl<sub>cr</sub> 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of gout flares, a treatment course should be repeated no more than once every two weeks. For patients with gout flares requiring repeated courses, consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of gout flares should be reduced to a single dose of 0.6 mg (one tablet). For these patients, the treatment course should not be repeated more than once every two weeks <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#www.splportal.comLINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">Use in Specific Populations (8.6)</linkHtml>]</content>. </paragraph>
                        <paragraph>Treatment of gout flares with colchicine tablets, USP is not recommended in patients with renal impairment who are receiving colchicine tablets, USP for prophylaxis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FMF</content>
                           <content styleCode="bold">
                              <br/>
                           </content>Caution should be taken in dosing patients with moderate and severe renal impairment and in patients undergoing dialysis. For these patients, the dosage should be reduced <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>].</content> Patients with mild (Cl<sub>cr</sub> 50 to 80 mL/min) and moderate (Cl<sub>cr</sub> 30 to 50 mL/min) renal impairment should be monitored closely for adverse effects of colchicine tablets, USP. Dose reduction may be necessary. For patients with severe renal failure (Cl<sub>cr</sub> less than 30 mL/min), start with 0.3 mg/day; any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">Use in Specific Populations (8.6)</linkHtml>]</content>
                           <content styleCode="italics">.</content> For patients undergoing dialysis, the total recommended starting dose should be 0.3 mg (half tablet) per day. Dosing can be increased with close monitoring. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#www.splportal.comLINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">Use in Specific Populations (8.6)</linkHtml>]</content>
                           <content styleCode="italics">. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1bffeea6-d605-419b-8747-dc2ce6e7d2ab">
                     <id root="ed81a359-789a-4cab-b499-0891510fbd48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dose Modification in Hepatic Impairment</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Gout Flares </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Prophylaxis of Gout Flares </content>
                        </paragraph>
                        <paragraph>For prophylaxis of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. Dose reduction should be considered for the prophylaxis of gout flares in patients with severe hepatic impairment<content styleCode="italics"> [see <linkHtml href="#www.splportal.comLINK_2b0ae298-167d-48cb-b287-ec916510434e">Use in Specific Populations (8.7)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Treatment of Gout Flares </content>
                        </paragraph>
                        <paragraph>For treatment of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, for the treatment of gout flares in patients with severe impairment, while the dose does not need to be adjusted, a treatment course should be repeated no more than once every two weeks. For these patients, requiring repeated courses for the treatment of gout flares, consideration should be given to alternate therapy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_2b0ae298-167d-48cb-b287-ec916510434e">Use in Specific Populations (8.7)</linkHtml>]</content>. </paragraph>
                        <paragraph>Treatment of gout flares with colchicine tablets, USP is not recommended in patients with hepatic impairment who are receiving colchicine tablets, USP for prophylaxis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FMF</content>
                           <content styleCode="bold">
                              <br/>
                           </content>Patients with mild to moderate hepatic impairment should be monitored closely for adverse effects of colchicine. Dose reduction should be considered in patients with severe hepatic impairment <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_2b0ae298-167d-48cb-b287-ec916510434e">Use in Specific Populations (8.7)</linkHtml>]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b0feee42-4a91-4c89-b8cc-5291fb6d67ac">
               <id root="2513ea64-ad7a-41c1-a79b-d18204ce21c3"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3Â  DOSAGE FORMS AND STRENGTHS 
</content>
               </title>
               <text>
                  <paragraph>Tablets: 0.6 mg colchicine - purple capsule-shaped, film-coated tablets, scored on one side and debossed with âA10â on the other side. </paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 0.6 mg colchicine (<linkHtml href="#LINK_b0feee42-4a91-4c89-b8cc-5291fb6d67ac">3</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_dcd2ff28-8d01-42d3-a3a2-2b3b768408b1">
               <id root="556b39f0-b7e9-4823-a289-c5888db67514"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4Â  CONTRAINDICATIONS 
</content>
               </title>
               <text>
                  <paragraph>Patients with renal or hepatic impairment should not be given colchicine, USP in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors except fosamprenavir). In these patients, life-threatening and fatal colchicine, USP toxicity has been reported with colchicine, USP taken in therapeutic doses.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> Patients with renal or hepatic impairment should not be given colchicine, USP in conjunction with P-gp or strong CYP3A4 inhibitors <linkHtml href="#LINK_9434393a-3a9a-4888-ba64-8b43f56009f9">(5.3)</linkHtml>. <br/>In these patients, life-threatening and fatal colchicine, USP toxicity has been reported with colchicine, USP taken in therapeutic doses <linkHtml href="#LINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">(7)</linkHtml>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0a02802f-68f7-49e2-be81-64279dc23c4f">
               <id root="e85cb5e9-3238-4dcc-ab83-4a4d0b64ac2c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5Â  WARNINGS AND PRECAUTIONS 
</content>
               </title>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics"> Fatal overdoses</content> have been reported with colchicine in adults and children. Keep colchicine out of the reach of children <linkHtml href="#LINK_a8033813-1930-4921-82c5-e27a7416469f">(5.1,</linkHtml>Â <linkHtml href="#LINK_8a2c852b-ac2f-41e8-9f24-a0bc1ca92827">10)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics"> Blood dyscrasias:</content> myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia have been reported <linkHtml href="#LINK_a256f550-665c-45b5-8a36-8a1f495f23d6">(5.2)</linkHtml>.</item>
                           <item> Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine <linkHtml href="#LINK_a256f550-665c-45b5-8a36-8a1f495f23d6">(5.2,</linkHtml>Â <linkHtml href="#LINK_9434393a-3a9a-4888-ba64-8b43f56009f9">5.3,</linkHtml>Â <linkHtml href="#LINK_91e06bc0-00a2-41a2-a8b3-4a47ada67a04">5.4,</linkHtml>Â <linkHtml href="#LINK_37d35fa5-204b-4635-b842-05c0b2367482">6,</linkHtml>Â <linkHtml href="#LINK_8a2c852b-ac2f-41e8-9f24-a0bc1ca92827">10)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics"> Drug interaction P-gp and/or CYP3A4 inhibitors:</content> Co-administration of colchicine with P-gp and/or strong CYP3A4 inhibitors has resulted in life-threatening interactions and death <linkHtml href="#LINK_9434393a-3a9a-4888-ba64-8b43f56009f9">(5.3,</linkHtml>Â <linkHtml href="#LINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">7)</linkHtml>.</item>
                           <item>
                              <content styleCode="italics"> Neuromuscular toxicity:</content> Myotoxicity including rhabdomyolysis may occur, especially in combination with other drugs known to cause this effect. Consider temporary interruption or discontinuation of colchicine <linkHtml href="#LINK_91e06bc0-00a2-41a2-a8b3-4a47ada67a04">(5.4,</linkHtml>Â <linkHtml href="#LINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">7)</linkHtml>.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_a8033813-1930-4921-82c5-e27a7416469f">
                     <id root="f4582bf1-20ad-4052-8e6a-5972d5bb5de3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Fatal Overdose</title>
                     <text>
                        <paragraph>Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_8a2c852b-ac2f-41e8-9f24-a0bc1ca92827">Overdosage (10)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content> Colchicine should be kept out of the reach of children.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a256f550-665c-45b5-8a36-8a1f495f23d6">
                     <id root="be06f150-6711-4a92-a573-9ef5c481b5b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Blood Dyscrasias</title>
                     <text>
                        <paragraph>Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia and aplastic anemia have been reported with colchicine used in therapeutic doses.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9434393a-3a9a-4888-ba64-8b43f56009f9">
                     <id root="e3d30aa9-5f72-4c67-90e3-09b85fa3887f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Drug Interactions</title>
                     <text>
                        <paragraph>Colchicine is a P-gp and CYP3A4 substrate. Life-threatening and fatal drug interactions have been reported in patients treated with colchicine given with P-gp and strong CYP3A4 inhibitors. If treatment with a P-gp or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, the patientâs dose of colchicine may need to be reduced or interrupted <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">Drug Interactions (7)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content> Use of colchicine in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors except fosamprenavir) is contraindicated in patients with renal or hepatic impairment <content styleCode="italics">[seeÂ </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_dcd2ff28-8d01-42d3-a3a2-2b3b768408b1">Contraindications (4)</linkHtml>
                           </content>
                           <content styleCode="italics">]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_91e06bc0-00a2-41a2-a8b3-4a47ada67a04">
                     <id root="318fbe7c-26d7-43e1-8357-00cebc83ff4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Neuromuscular Toxicity</title>
                     <text>
                        <paragraph>Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid or benzafibrate (themselves associated with myotoxicity) or cyclosporine with colchicine may potentiate the development of myopathy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">Drug Interactions (7)</linkHtml>].</content> Once colchicine is stopped, the symptoms generally resolve within one week to several months. </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_37d35fa5-204b-4635-b842-05c0b2367482">
               <id root="26426f8c-2617-4e47-a1ad-df1289dd0a80"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6Â  ADVERSE REACTIONS </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Prophylaxis of Gout Flares </content>
                  </paragraph>
                  <paragraph>The most commonly reported adverse reaction in clinical trials of colchicine for the prophylaxis of gout was diarrhea. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Treatment of Gout Flares </content>
                  </paragraph>
                  <paragraph>The most common adverse reactions reported in the clinical trial with colchicine for treatment of gout flares were diarrhea (23%) and pharyngolaryngeal pain (3%).</paragraph>
                  <paragraph>
                     <content styleCode="underline">FMF</content>
                  </paragraph>
                  <paragraph>Gastrointestinal tract adverse effects are the most frequent side effects in patients initiating colchicine, usually presenting within 24 hours, and occurring in up to 20% of patients given therapeutic doses. Typical symptoms include cramping, nausea, diarrhea, abdominal pain and vomiting. These events should be viewed as dose-limiting if severe, as they can herald the onset of more significant toxicity.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold">Prophylaxis of Gout Flares:</content> The most commonly reported adverse reaction in clinical trials for the prophylaxis of gout was diarrhea.</item>
                           <item>
                              <content styleCode="bold">
                                 <content styleCode="bold">Treatment of Gout Flares: </content>
                              </content>The most common adverse reactions reported in the clinical trial for gout were diarrhea (23%) and pharyngolaryngeal pain (3%).</item>
                           <item>
                              <content styleCode="bold">FMF:</content> Most common adverse reactions (up to 20%) are abdominal pain, diarrhea, nausea and vomiting. These effects are usually mild, transient and reversible upon lowering the dose <linkHtml href="#LINK_37d35fa5-204b-4635-b842-05c0b2367482">(6)</linkHtml>. </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_83cbd8d0-ec47-474b-b5d9-af26cfac0fb1">
                     <id root="f6a356cc-552c-42bb-8a5c-e679511424cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials
Experience in Gout</title>
                     <text>
                        <paragraph>Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice. </paragraph>
                        <paragraph>In a randomized, double-blind, placebo-controlled trial in patients with a gout flare, gastrointestinal adverse reactions occurred in 26% of patients using the recommended dose (1.8 mg over one hour) of colchicine compared to 77% of patients taking a non-recommended high dose (4.8 mg over six hours) of colchicine and 20% of patients taking placebo. Diarrhea was the most commonly reported drug-related gastrointestinal adverse event. As shown in <content styleCode="italics">Table 3</content>, diarrhea is associated with colchicine treatment. Diarrhea was more likely to occur in patients taking the high-dose regimen than the low-dose regimen. Severe diarrhea occurred in 19% and vomiting occurred in 17% of patients taking the non-recommended high-dose colchicine regimen but did not occur in the recommended low-dose colchicine regimen. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3. Number (%) of Patients with at Least One Drug-Related Treatment-Emergent Adverse Event with an Incidence of â¥2% of Patients in Any Treatment Group</content>
                        </paragraph>
                        <table width="100%" cellspacing="0" cellpadding="0" border="1">
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">MedDRA System Organ Class </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">MedDRA Preferred Term</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Colchicine Dose</content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=59) </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">High (N=52) </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%) </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Low (N=74) </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Number of Patients with at Least One Drug-Related TEAE </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>40 (77)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>27 (37)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>16 (27)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Gastrointestinal Disorders </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>40 (77)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>19 (26)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12 (20)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Diarrhea </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>40 (77)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>17 (23)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8 (14)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nausea </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9 (17)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Vomiting </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9 (17)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Abdominal Discomfort </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>General Disorders and Administration Site Conditions </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4 (8)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (1)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Fatigue </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (1)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Metabolic and Nutrition Disorders </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Gout </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nervous System Disorders </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (1.4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Headache </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (1)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Respiratory Thoracic Mediastinal Disorders </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (3)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pharyngolaryngeal Pain </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (3)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_38cbb48c-1a2a-4f16-bba4-012b58366ed3">
                     <id root="2a714739-ed43-4055-b950-0f9200898b3d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>Serious toxic manifestations associated with colchicine include myelosuppression, disseminated intravascular coagulation and injury to cells in the renal, hepatic, circulatory and central nervous systems.</paragraph>
                        <paragraph>These most often occur with excessive accumulation or overdosage <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_8a2c852b-ac2f-41e8-9f24-a0bc1ca92827">Overdosage (10)</linkHtml>
                           </content>
                           <content styleCode="italics">]. </content>
                        </paragraph>
                        <paragraph>The following adverse reactions have been identified with colchicine. These have been generally reversible upon temporarily interrupting treatment or lowering the dose of colchicine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Neurological:</content> sensory motor neuropathy </paragraph>
                        <paragraph>
                           <content styleCode="italics">Dermatological:</content> alopecia, maculopapular rash, purpura, rash </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive:</content> abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematological:</content> leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary:</content> elevated AST, elevated ALT </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal:</content> myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis </paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive:</content> azoospermia, oligospermia </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">
               <id root="e5b5d4fc-8881-4b12-90f9-3e690939eecd"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7Â  DRUG INTERACTIONS 
</content>
               </title>
               <text>
                  <paragraph>Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was mainly involved in the metabolism of colchicine. If colchicine is administered with drugs that inhibit P-gp, most of which also inhibit CYP3A4, increased concentrations of colchicine are likely. Fatal drug interactions have been reported. </paragraph>
                  <paragraph>Physicians should ensure that patients are suitable candidates for treatment with colchicine and remain alert for signs and symptoms of toxicities related to increased colchicine exposure as a result of a drug interaction. Signs and symptoms of colchicine toxicity should be evaluated promptly and, if toxicity is suspected, colchicine should be discontinued immediately. </paragraph>
                  <paragraph>
                     <content styleCode="italics">Table 4</content> provides recommendations as a result of other potentially significant drug interactions. <content styleCode="italics">Table 1</content> provides recommendations for strong and moderate CYP3A4 inhibitors and P-gp inhibitors.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 4. Other Potentially Significant Drug Interactions</content>
                  </paragraph>
                  <table width="100%">
                     <col width="17pt"/>
                     <col width="17pt"/>
                     <col width="17pt"/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Concomitant Drug Class or Â Food</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Noted or Anticipated Outcome</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Clinical Comment</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">HMG-Co A Reductase<br/> Inhibitors:</content>
                              <br/> atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin</td>
                           <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Pharmacokinetic and/or pharmacodynamic<br/> interaction: the addition of one drug to a Â stable long-term regimen of the other has Â resulted in myopathy and rhabdomyolysis (including a fatality)</td>
                           <td rowspan="3" styleCode=" Botrule Toprule Lrule Rrule">Weigh the potential benefits and risks and<br/> carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during initial<br/> therapy; monitoring CPK (creatine<br/> phosphokinase) will not necessarily prevent Â the occurrence of severe myopathy.</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Other Lipid-Lowering Drugs:<br/>
                              </content>fibrates, gemfibrozil</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">Digitalis Glycosides:<br/>
                              </content>digoxin</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">P-gp substrate; rhabdomyolysis has been<br/> reported</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph> Co-administration of P-gp and/or CYP3A4 inhibitors (e.g., clarithromycin or cyclosporine) have been demonstrated to alter the concentration of colchicine. The potential for drug-drug interactions must be considered prior to and during therapy. See FPI for a complete list of reported and potential interactions <linkHtml href="#LINK_46b96977-a66c-4790-bdb2-a0f65ed76028">(2.4,</linkHtml>Â <linkHtml href="#LINK_9434393a-3a9a-4888-ba64-8b43f56009f9">5.3,</linkHtml>Â <linkHtml href="#LINK_25c389c7-aefd-4a4e-8ff0-9506bedaf209">7)</linkHtml>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8b540177-2c64-4ed3-ad36-0c4b40f8afb5">
               <id root="2803ae0d-2389-4e2d-af37-e6bf7847d0b0"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8Â  USE IN SPECIFIC POPULATIONS </content>
               </title>
               <text/>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>In the presence of mild to moderate renal or hepatic impairment, adjustment of dosing is not required for treatment of gout flare, prophylaxis of gout flare and FMF, but patients should be monitored closelyÂ <linkHtml href="#LINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">(</linkHtml>
                              <linkHtml href="#LINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">8.6)</linkHtml>. 
</item>
                           <item>In patients with severe renal impairment for prophylaxis of gout flares, the starting dose should be 0.3 mg/day for gout flares, no dose adjustment is required, but a treatment course should be repeated no more than once every two weeks. In FMF patients, start with 0.3 mg/day and any increase in dose should be done with close monitoringÂ <linkHtml href="#LINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">(</linkHtml>
                              <linkHtml href="#LINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">8.6)</linkHtml>. 
</item>
                           <item>InÂ patients with severe hepatic impairment, a dose reduction may be neededÂ in prophylaxis of gout flares and FMF patients; while a dose reduction may not be needed in gout flares, a treatment course should be repeated no more than once every two weeksÂ <linkHtml href="#LINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">(</linkHtml>
                              <linkHtml href="#LINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">8.6,</linkHtml>Â <linkHtml href="#LINK_2b0ae298-167d-48cb-b287-ec916510434e">8.7)</linkHtml>. 
</item>
                           <item>For patients undergoing dialysis, the total recommended dose for prophylaxis of gout flares should be 0.3 mg given twice a week with close monitoring. For treatment of gout flares, the total recommended dose should be reduced to 0.6 mg (one tablet) x 1 dose and the treatment course should not be repeated more than once every two weeks. For FMF patients, the starting dose should be 0.3 mg/day and dosing can be increased with close monitoringÂ <linkHtml href="#LINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">(</linkHtml>
                              <linkHtml href="#LINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">8.6)</linkHtml>.</item>
                           <item>Females and Males of Reproductive Potential: Advise males that colchicine may transiently impair fertility (8.3).</item>
                           <item>Geriatric Use: The recommended dose of colchicine should be based on renal functionÂ <linkHtml href="#LINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">(</linkHtml>
                              <linkHtml href="#LINK_17a72a91-341e-44f1-ae76-3f20a780e620">8.5)</linkHtml>. </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_267a418e-fa29-4234-af0c-0a20bbd70525">
                     <id root="6549a13a-fc27-42f8-9b93-8c48c694e956"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Available data from published literature on colchicine use in pregnancy over several decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes <content styleCode="italics">(see Data). </content>Colchicine crosses the human placenta. Although animal reproductive and developmental studies were not conducted with colchicine, published animal reproduction and development studies indicate that colchicine causes embryofetal toxicity, teratogenicity and altered postnatal development at exposures within or above the clinical therapeutic range. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>
                        </paragraph>
                        <paragraph>Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects or miscarriage in pregnant women with rheumatic diseases (such as rheumatoid arthritis, Behcetâs disease, or familial Mediterranean fever (FMF) treated with colchicine at therapeutic doses during pregnancy. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications. </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4d3ce58f-200c-476c-a36f-ace3fd038468">
                     <id root="3eb8bced-5fd6-405f-9c8c-0b87e159fc8c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Colchicine is present in human milk <content styleCode="italics">(see Data)</content>. Adverse events in breastfed infants have not been reported in the published literature after administration of colchicine to lactating women. There are no data on the effects of colchicine on milk production. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for colchicine and any potential adverse effects on the breastfed child from colchicine or from the underlying maternal condition. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>Limited published data from case reports and a small lactation study demonstrate that colchicine is present in breastmilk. A systematic review of literature reported no adverse effects in 149 breastfed children. In a prospective observational cohort study, no gastrointestinal or other symptoms were reported in 38 colchicine-exposed breastfed infants. </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4850c610-a169-449f-9355-21fb173ac103">
                     <id root="e813a1a4-c87a-4eda-a1f5-2d40548c4418"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females
and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility </content>
                        </paragraph>
                        <paragraph>Case reports and epidemiology studies in human male subjects on colchicine therapy indicated that infertility from colchicine is rare and may be reversible. A case report indicated that azoospermia was reversed when therapy was stopped. Case reports and epidemiology studies in female subjects on colchicine therapy have not established a clear relationship between colchicine use and female infertility. However, since the progression of FMF without treatment may result in infertility, the use of colchicine needs to be weighed against the potential risks <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_614a7dbf-5ab9-4bf0-8247-dbb179316c47">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ac363da2-057a-4ad1-a652-b7f464191bd0">
                     <id root="518ec291-08ec-4449-a58a-01c77e131240"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of colchicine in children of all ages with FMF has been evaluated in uncontrolled studies. There does not appear to be an adverse effect on growth in children with FMF treated long-term with colchicine. Safety and effectiveness of colchicine in pediatric patients with gout has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_17a72a91-341e-44f1-ae76-3f20a780e620">
                     <id root="17430499-4cdd-4d1c-89fc-b424e6772995"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies with colchicine for prophylaxis and treatment of gout flares and for treatment of FMF did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient with gout should be cautious, reflecting the greater frequency of decreased renal function, concomitant disease or other drug therapy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_46b96977-a66c-4790-bdb2-a0f65ed76028">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>]</content>
                           <content styleCode="italics">. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">
                     <id root="7df7fa6a-197d-4c23-a4fa-ce68f2d620eb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Total body clearance of colchicine was reduced by 75% in patients with end-stage renal disease undergoing dialysis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Prophylaxis of Gout Flares </content>
                        </paragraph>
                        <paragraph>For prophylaxis of gout flares in patients with mild (estimated creatinine clearance Cl<sub>cr</sub> 50 to 80 mL/min) to moderate (Cl<sub>cr</sub> 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg per day and any increase in dose should be done with close monitoring. For the prophylaxis of gout flares in patients undergoing dialysis, the starting doses should be 0.3 mg given twice a week with close monitoring <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">Dosage and Administration (2.5)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Treatment of Gout Flares </content>
                        </paragraph>
                        <paragraph>For treatment of gout flares in patients with mild (Cl<sub>cr</sub> 50 to 80 mL/min) to moderate (Cl<sub>cr</sub> 30 to 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of gout flares, a treatment course should be repeated no more than once every two weeks. For patients with gout flares requiring repeated courses, consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of gout flares should be reduced to a single dose of 0.6 mg (one tablet). For these patients, the treatment course should not be repeated more than once every two weeks <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">Dosage and Administration (2.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FMF </content>
                        </paragraph>
                        <paragraph>Although pharmacokinetics of colchicine in patients with mild (Cl<sub>cr</sub> 50 toÂ  80 mL/min) and moderate (Cl<sub>cr</sub> 30 to 50 mL/min) renal impairment is not known, these patients should be monitored closely for adverse effects of colchicine. Dose reduction may be necessary. In patients with severe renal failure (Cl<sub>cr</sub> less than 30 mL/min) and end-stage renal disease requiring dialysis, colchicine may be started at the dose of 0.3 mg/day. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#www.splportal.comLINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">Dosage and Administration (2.5)</linkHtml>]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2b0ae298-167d-48cb-b287-ec916510434e">
                     <id root="7d4a2d71-bfe9-4693-8f4e-1a1ea13699e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subjects <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Prophylaxis of Gout Flares </content>
                        </paragraph>
                        <paragraph>For prophylaxis of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. Dose reduction should be considered for the prophylaxis of gout flares in patients with severe hepatic impairmentÂ <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_1bffeea6-d605-419b-8747-dc2ce6e7d2ab">Dosage and Administration (2.6)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Treatment of Gout Flares </content>
                        </paragraph>
                        <paragraph>For treatment of gout flares in patients with mild to moderate hepatic function impairment, adjustment of the recommended colchicine dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, for the treatment of gout flares in patients with severe impairment, while the dose does not need to be adjusted, the treatment course should be repeated no more than once every two weeks. For these patients, requiring repeated courses for the treatment of gout flares, consideration should be given to alternate therapy <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_1bffeea6-d605-419b-8747-dc2ce6e7d2ab">Dosage and Administration (2.6)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FMF </content>
                           <content styleCode="bold">
                              <br/>
                           </content>In patients with severe hepatic disease, dose reduction should be considered with careful monitoring <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#www.splportal.comLINK_1bffeea6-d605-419b-8747-dc2ce6e7d2ab">Dosage and Administration (2.6)</linkHtml>]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f232cf12-d1f3-4d03-9484-05b6994a6c7b">
               <id root="465b29b2-ab07-441d-8ecf-cfcf1a505cfe"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>
                  <content styleCode="bold">9Â  DRUG ABUSE AND DEPENDENCE 
</content>
               </title>
               <text>
                  <paragraph>Tolerance, abuse or dependence with colchicine has not been reported.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="LINK_8a2c852b-ac2f-41e8-9f24-a0bc1ca92827">
               <id root="8a7c69f3-8268-4fb9-bc26-4c82c88249fe"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10Â  OVERDOSAGE 
</content>
               </title>
               <text>
                  <paragraph>The exact dose of colchicine that produces significant toxicity is unknown. Fatalities have occurred after ingestion of a dose as low as 7 mg over a four day period, while other patients have survived after ingesting more than 60 mg. A review of 150 patients who overdosed on colchicine found that those who ingested less than 0.5 mg/kg survived and tended to have milder toxicities such as gastrointestinal symptoms, whereas those who took 0.5 to 0.8 mg/kg had more severe reactions such as myelosuppression. There was 100% mortality in those who ingested more than 0.8 mg/kg. </paragraph>
                  <paragraph>The first stage of acute colchicine toxicity typically begins within 24 hours of ingestion and includes gastrointestinal symptoms such as abdominal pain, nausea, vomiting, diarrhea and significant fluid loss, leading to volume depletion. Peripheral leukocytosis may also be seen. Life-threatening complications occur during the second stage, which occurs 24 to 72 hours after drug administration, attributed to multiorgan failure and its consequences. Death is usually a result of respiratory depression and cardiovascular collapse. If the patient survives, recovery of multiorgan injury may be accompanied by rebound leukocytosis and alopecia starting about one week after the initial ingestion. </paragraph>
                  <paragraph>Treatment of colchicine poisoning should begin with gastric lavage and measures to prevent shock. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. Colchicine is not effectively removed by dialysis <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">Clinical Pharmacology (12.3)</linkHtml>]</content>
                     <content styleCode="italics">. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="LINK_93ea8c30-8ebe-439d-8d27-3824c2c7b766">
               <id root="08787855-4734-439f-ae57-c9ac61b7ec42"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11Â  DESCRIPTION 
</content>
               </title>
               <text>
                  <paragraph>Colchicine, USP is an alkaloid chemically described as (S)N- (5,6,7,9-tetrahydro- 1,2,3, 10-tetramethoxy-9-oxobenzo [alpha] heptalen-7-yl) acetamide with a molecular formula of C<sub>22</sub>H<sub>25</sub>NO<sub>6</sub> and a molecular weight of 399.4. The structural formula of colchicine, USP is given below.</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Colchicine, USP occurs as a pale yellow powder that is soluble in water.</paragraph>
                  <paragraph>Colchicine tablets, USP are supplied for oral administration as purple, capsule-shaped, film-coated tablets, scored on one side and debossed with âA10â on the other, containing 0.6 mg of the active ingredient colchicine, USP. Inactive ingredients: ethanol, FD&amp;C blue #2, FD&amp;C red #40, hypromellose, lactose monohydrate, macrogol, magnesium stearate, microcrystalline cellulose, polydextrose, pregelatinized starch (corn), purified water, sodium starch glycolate, titanium dioxide and triacetin.</paragraph>
                  <paragraph>USP Dissolution Test Pending.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>30a820b8-figure-01</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="colchicine-tablets-usp-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_493cd16c-c2a4-42d2-884d-123b5bcd9a37">
               <id root="0d1cb2e0-0fa4-4f0d-aed9-93f275b343cc"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12Â  CLINICAL PHARMACOLOGY 
</content>
               </title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="LINK_cc891c6f-be76-415c-a0ec-2095e9e8fc3a">
                     <id root="ab3367af-e799-43bd-b5e5-d4f75db6f703"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism by which colchicine exerts its beneficial effect in patients with FMF has not been fully elucidated; however, evidence suggests that colchicine may interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1Î². Additionally, colchicine disrupts cytoskeletal functions through inhibition of Î²-tubulin polymerization into microtubules and consequently prevents the activation, degranulation and migration of neutrophils thought to mediate some gout symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b6ccd72f-5777-4e11-a63f-1cb39a3a04c9">
                     <id root="785f5dba-b417-4ba9-be3d-4458f5c65e2d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>In healthy adults, colchicine is absorbed when given orally, reaching a mean C<sub>max</sub> of 2.5 ng/mL (range 1.1 to 4.4 ng/mL) in one to two hours (range 0.5 to 3 hours) after a single dose administered under fasting conditions. </paragraph>
                        <paragraph>Following oral administration of colchicine given as 1.8 mg colchicine over one hour to healthy, young adults under fasting conditions, colchicine appears to be readily absorbed, reaching mean maximum plasma concentrations of 6.2 ng/mL at a median 1.81 hours (range: 1 to 2.5 hours). Following administration of the nonrecommended high-dose regimen (4.8 mg over six hours), mean maximal plasma concentrations were 6.8 ng/mL, at a median 4.47 hours (range: 3.1 to 7.5 hours).</paragraph>
                        <paragraph>After ten days on a regimen of 0.6 mg twice daily, peak concentrations are 3.1 to 3.6 ng/mL (range 1.6 to 6 ng/mL), occurring 1.3 to 1.4 hours post dose (range 0.5 to 3 hours). Mean pharmacokinetic parameter values in healthy adults are shown in <content styleCode="italics">Table 5</content>. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 5. Mean (%CV) Pharmacokinetic Parameters in Healthy Adults Given Colchicine</content>
                        </paragraph>
                        <table width="100%" cellspacing="0" cellpadding="0" border="1">
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub> (Colchicine ng/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">T<sub>max</sub>
                                          <sup>*</sup> (h)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Vd/F (L)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">CL/F (L/hr)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">t<sub>1/2</sub> (h)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Colchicine 0.6 mg Single Dose (N=13)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.5 (28.7)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.5 (1 to 3)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>341.5 (54.4)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>54.1 (31)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>--</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Colchicine 0.6 mg Twice Daily x 10 days (N =13)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3.6 (23.7)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.3 (0.5 to 3)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1150 (18.7)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>30.3 (19)</paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>26.6 (16.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <sup>*</sup> T<sub>max</sub> mean (range) </paragraph>
                                    <paragraph>CL = Dose/AUC<sub>0-t</sub> (calculated from mean values) </paragraph>
                                    <paragraph>Vd = CL/Ke (calculated from mean values) </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Â In some subjects, secondary colchicine peaks are seen, occurring between three and 36 hours post dose and ranging from 39% to 155% of the height of the initial peak. These observations are attributed to intestinal secretion and reabsorption and/or biliary recirculation. </paragraph>
                        <paragraph>Absolute bioavailability is reported to be approximately 45%. </paragraph>
                        <paragraph>Administration of colchicine with food has no effect on the rate of colchicine absorption but does decrease the extent of colchicine by approximately 15%. This is without clinical significance. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution </content>
                        </paragraph>
                        <paragraph>The mean apparent volume of distribution in healthy young volunteers is approximately 5 to 8 L/kg. </paragraph>
                        <paragraph>Colchicine binding to serum protein is low, 39 Â± 5%, primarily to albumin regardless of concentration. </paragraph>
                        <paragraph>Colchicine crosses the placenta (plasma levels in the fetus are reported to be approximately 15% of the maternal concentration). Colchicine also distributes into breast milk at concentrations similar to those found in the maternal serum <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_267a418e-fa29-4234-af0c-0a20bbd70525">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_4d3ce58f-200c-476c-a36f-ace3fd038468">8.2</linkHtml>)]</content>
                           <content styleCode="italics">. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism </content>
                        </paragraph>
                        <paragraph>Colchicine is demethylated to two primary metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively) and one minor metabolite, 10-O-demethylcolchicine (also known as colchicine). <content styleCode="italics">In vitro</content> studies using human liver microsomes have shown that CYP3A4 is involved in the metabolism of colchicine to 2- and 3-DMC. Plasma levels of these metabolites are minimal (less than 5% of parent drug). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination/Excretion </content>
                        </paragraph>
                        <paragraph>In healthy volunteers (n=12), 40% to 65% of 1 mg orally administered colchicine was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also postulated to play a role in colchicine elimination. Following multiple oral doses (0.6 mg twice daily), the mean elimination half-lives in young healthy volunteers (mean age 25 to 28 years of age) is 26.6 to 31.2 hours. Colchicine is a substrate of P-gp. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Extracorporeal Elimination </content>
                        </paragraph>
                        <paragraph>Colchicine is not removed by hemodialysis. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Special Populations </content>
                        </paragraph>
                        <paragraph>There is no difference between men and women in the pharmacokinetic disposition of colchicine. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>Pharmacokinetics of colchicine was not evaluated in pediatric patients. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Elderly</content>
                        </paragraph>
                        <paragraph>A published report described the pharmacokinetics of 1 mg oral colchicine tablet in four elderly women compared to six young healthy males. The mean age of the four elderly women was 83 years (range 75 to 93), mean weight was 47 kg (38 to 61 kg) and mean creatinine clearance was 46 mL/min (range 25 to 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males. </paragraph>
                        <paragraph>A pharmacokinetic study using a single oral dose of one 0.6 mg colchicine tablet was conducted in young healthy subjects (n=20) between the ages of 18 and 30 years and elderly subjects (n=18) between the ages of 60 and 70 years. Elderly subjects in this study had a median age of 62 years and a mean (Â±SD) age of 62.83 Â± 2.83 years. A statistically significant difference in creatinine clearance (mean Â± SD) was found between the two age groups (132.56 Â± 23.16 mL/min for young vs. 87.02 Â± 17.92 mL/min for elderly subjects, respectively). The following pharmacokinetic parameter values (mean Â± SD) were observed for colchicine in the young and elderly subjects, respectively: AUC<sub>0-inf</sub> (ng/hr/mL) 22.39 Â± 6.95 and 25.01 Â± 6.92; C<sub>max</sub> (ng/mL) 2.61 Â± 0.71 and 2.56 Â± 0.97; T<sub>max</sub> (hr) 1.38 Â± 0.42 and 1.25 Â± 0.43; apparent elimination half-life (hr) 24.92 Â± 5.34 and 30.06 Â± 10.78; and clearance (mL/min) 0.0321 Â± 0.0091 and 0.0292 Â± 0.0071. </paragraph>
                        <paragraph>Clinical studies with colchicine prophylaxis and treatment of gout flares and for treatment of FMF did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient with gout should be cautious, reflecting the greater frequency of decreased renal function, concomitant disease or other drug therapy <content styleCode="italics">
                              <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_46b96977-a66c-4790-bdb2-a0f65ed76028">Dosage and Administration (2.4)</linkHtml>
                              </content>
                           </content>,<content styleCode="italics">
                              <content styleCode="italics">
                                 <linkHtml href="#www.splportal.comLINK_17a72a91-341e-44f1-ae76-3f20a780e620"> Use in Specific Populations (8.5)</linkHtml>]</content>
                           </content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>Pharmacokinetics of colchicine in patients with mild and moderate renal impairment is not known. A published report described the disposition of colchicine (1 mg) in young adult men and women with FMF who had normal renal function or end-stage renal disease requiring dialysis. Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 vs. 4.4 hours) as compared to subjects with FMF and normal renal function <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_3fe46f26-bfea-4d63-886f-9141cd0715e4">Dosage and Administration (2.5)</linkHtml>, <linkHtml href="#www.splportal.comLINK_bb5e8c1a-68d5-43b9-a57d-7b68f3fa9cb9">Use in Specific Populations (8.6)</linkHtml>]</content>
                           <content styleCode="italics">. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Published reports on the pharmacokinetics of IV colchicine in patients with severe chronic liver disease, as well as those with alcoholic or primary biliary cirrhosis and normal renal function suggest wide interpatient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with primary biliary cirrhosis, no consistent trends were noted <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_1bffeea6-d605-419b-8747-dc2ce6e7d2ab">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#www.splportal.comLINK_2b0ae298-167d-48cb-b287-ec916510434e">Use in Specific Populations (8.7)</linkHtml>]</content>
                           <content styleCode="italics">.</content> No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 activity. </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vivo Drug Interactions</content>
                        </paragraph>
                        <paragraph>The effects of co-administration of other drugs with colchicine on C<sub>max</sub>, AUC and C<sub>min</sub> are summarized in <content styleCode="italics">Table 6</content> (effect of other drugs on colchicine) and <content styleCode="italics">Table 7</content> (effect of colchicine on other drugs). For information regarding clinical recommendations, see <content styleCode="italics">Table 1</content> in Dose Modification for Co-administration of Interacting Drugs <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_46b96977-a66c-4790-bdb2-a0f65ed76028">Dosage and Administration (2.4)</linkHtml>]</content>
                           <content styleCode="italics">. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 6. Drug Interactions: Pharmacokinetic Parameters for Colchicine Tablets in the Presence of the Co-Administered Drug</content>
                        </paragraph>
                        <table width="100%">
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">Co-administered Drug</content>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="bold">Dose of <br/> Co-administered Drug <br/> (mg)</content>Â </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">Dose of <br/> Colchicine<br/> (mg)</content>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">N</content>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">% Change in Colchicine<br/> Concentrations from Baseline<br/>
                                       <br/> (Range: Min to Max)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">C<sub>max</sub>
                                    </content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">AUC<sub>0-t</sub>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â Cyclosporine </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 100 mg <br/> single dose </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">0.6 mg <br/> single dose Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">23Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">270<br/>(62 to 606.9)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">259<br/>(75.8 to 511.9)Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Clarithromycin Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">250 mg twice daily, <br/> 7 days Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">0.6 mg <br/> single dose Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">23Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 227.2 <br/> (65.7 to 591.1)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 281.5 <br/> (88.7 to 851.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Ketoconazole Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">200 mg twice daily, <br/> 5 days Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 0.6 mg <br/> single dose </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">24Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">101.7 <br/> (19.6 to 219)Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 212.2 <br/> (76.7 to 419.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Ritonavir Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">100 mg twice daily, <br/> 5 days Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">0.6 mg <br/> single dose Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">18</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">184.4 <br/> (79.2 to 447.4)Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 296 <br/> (53.8 to 924.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â Verapamil </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">240 mg daily, <br/> 5 days Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">0.6 mg <br/> single dose Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">24</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 40.1 <br/> (-47.1 to 149.5)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">103.3 <br/> (-9.8 to 217.2)Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">DiltiazemÂ </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 240 mg daily, <br/> 7 days </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 0.6 mg <br/> single dose </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">20Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 44.2 <br/> (-46 to 318.3)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 93.4 <br/> (-30.2 to 338.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Azithromycin Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 500 mg Ã 1 day, then <br/> 250 mg Ã 4 days </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 0.6 mg <br/> single dose </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">21Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â 21.6 <br/> (-41.7 to 222)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">57.1 <br/> (-24.3 to 241.1)Â </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â Grapefruit juice </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">240 mL twice daily, <br/> 4 days Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">0.6 mg <br/> single dose Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">21Â </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â -2.55 <br/> (-53.4 to 55)</td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â -2.36 <br/> (-46.4 to 62.2)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Estrogen-containing oral contraceptives: In healthy female volunteers given ethinyl estradiol and norethindrone (Ortho-Novum 1/35) co-administered with colchicine (0.6 mg twice daily Ã 14 days), hormone concentrations are not affected. </paragraph>
                        <paragraph>In healthy volunteers given theophylline co-administered with colchicine (0.6 mg twice daily Ã 14 days), theophylline concentrations were not affected. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 7. Drug Interactions: Pharmacokinetic Parameters for Co-Administration of Drug in the Presence of Colchicine Tablets</content>
                        </paragraph>
                        <table width="100%">
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col width="17pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>
                                       <content styleCode="bold">Co-administered </content>
                                    </paragraph>
                                    <content styleCode="bold">Drug</content>
                                 </td>
                                 <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Dose of </content>
                                    </paragraph>
                                    <content styleCode="bold">Co-administered <br/> Drug (mg)</content>Â </td>
                                 <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>
                                       <content styleCode="bold">Dose of </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Colchicine</content>
                                    </paragraph>
                                    <content styleCode="bold">(mg)</content>
                                 </td>
                                 <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">N</content>
                                 </td>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>
                                       <content styleCode="bold">% Change in Co-Administered</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Drug Concentrations from Baseline</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Â </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(Range: Min to Max)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">C<sub>max</sub>
                                    </content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">AUC<sub>0-t</sub>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â Theophylline</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>300 mg (elixir) </paragraph> single dose</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 0.6 mg twice daily x 14 days</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â 27</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>1.6 </paragraph> (-30.4 to 23.1)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>1.6 </paragraph> (-28.5 to 27.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>Ethinyl Estradiol</paragraph> (Ortho-Novum 1/35)</td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>21-day cycle</paragraph>
                                    <paragraph>(active treatment)</paragraph>
                                    <paragraph>+ 7-day placebo</paragraph>
                                 </td>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>0.6 mg twice daily x 14 days</paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â 27<sup>*</sup>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>-6.7</paragraph> (-40.3 to 44.7)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>-3<sup>â </sup>
                                    </paragraph>
                                    <paragraph> (-25.3 to 24.9)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>Norethindrone</paragraph> (Ortho-Novum 1/35)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>0.94</paragraph> (-37.3 to 59.4)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">Â  <paragraph>-1.6<sup>â </sup>
                                    </paragraph> (-32 to 33.7)</td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode=" Botrule Toprule Lrule Rrule">Â <paragraph>
                                       <sup>*</sup> Conducted in healthy adult females</paragraph>
                                    <sup>â </sup> AUCÏ</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c6aec50e-010b-47ab-b790-7ed587bbb7d4">
               <id root="26779f9e-57f8-48ad-bf1f-8bbe51abb470"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13Â  NONCLINICAL TOXICOLOGY 
</content>
               </title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="LINK_614a7dbf-5ab9-4bf0-8247-dbb179316c47">
                     <id root="c982040b-cb0d-4d3c-bbb6-9b3951b358ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Carcinogenesis </content>
                        </paragraph>
                        <paragraph>Two year studies were conducted in mice and rats to assess the carcinogenic potential of colchicine. No evidence of colchicine-related tumorigenicity was observed in mice or rats at colchicine oral doses up to 3 and 2 mg/kg/day, respectively (approximately six and eight times, respectively, the maximum recommended human dose of 2.4 mg on a mg/m<sup>2</sup> basis).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Mutagenesis </content>
                        </paragraph>
                        <paragraph>Colchicine was negative for mutagenicity in the bacterial reverse mutation assay. In a chromosomal aberration assay in cultured human white blood cells, colchicine treatment resulted in the formation of micronuclei. Since published studies demonstrated that colchicine induces aneuploidy from the process of mitotic nondisjunction without structural DNA changes, colchicine is not considered clastogenic, although micronuclei are formed. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Impairment of Fertility </content>
                        </paragraph>
                        <paragraph>No studies of colchicine effects on fertility were conducted with colchicine. However, published nonclinical studies demonstrated that colchicine-induced disruption of microtubule formation affects meiosis and mitosis. Reproductive studies also reported abnormal sperm morphology and reduced sperm counts in males, and interference with sperm penetration, second meiotic division and normal cleavage in females when exposed to colchicine. Colchicine administered to pregnant animals resulted in fetal death and teratogenicity. These effects were dose-dependent, with the timing of exposure critical for the effects on embryofetal development. The nonclinical doses evaluated were generally higher than an equivalent human therapeutic dose, but safety margins for reproductive and developmental toxicity could not be determined. </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a081fe00-c929-4118-b57a-83517b6435cc">
               <id root="764b8f73-5caa-4c9b-b56e-0692c66a0289"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14Â  CLINICAL STUDIES </content>
               </title>
               <text>
                  <paragraph>The evidence for the efficacy of colchicine in patients with chronic gout is derived from the published literature. Two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of gout flares in patients with gout initiating treatment with urate-lowering therapy. In both trials, treatment with colchicine decreased the frequency of gout flares. </paragraph>
                  <paragraph>The efficacy of a low-dosage regimen of oral colchicine (colchicine total dose 1.8 mg over one hour) for treatment of gout flares was assessed in a multicenter, randomized, double-blind, placebo-controlled, parallel group, one week, dose-comparison study. Patients meeting American College of Rheumatology criteria for gout were randomly assigned to three groups: high-dose colchicine (1.2 mg, then 0.6 mg hourly Ã 6 hours </paragraph>
                  <paragraph>[4.8 mg total]); low-dose colchicine (1.2 mg, then 0.6 mg in one hour [1.8 mg total] followed by five placebo doses hourly); or placebo (two capsules, then one capsule hourly Ã six hours). Patients took the first dose within 12 hours of the onset of the flare and recorded pain intensity (11-point Likert scale) and adverse events over 72 hours. The efficacy of colchicine was measured based on response to treatment in the target joint, using patient self-assessment of pain at 24 hours following the time of first dose as recorded in the diary. A responder was one who achieved at least a 50% reduction in pain score at the 24-hour post dose assessment relative to the pretreatment score and did not use rescue medication prior to the actual time of 24-hour post dose assessment. </paragraph>
                  <paragraph>Rates of response were similar for the recommended low-dose treatment group (38%) and the non-recommended high-dose group (33%) but were higher as compared to the placebo group (16%) as shown in <content styleCode="italics">Table 8</content>. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 8. Number (%) of Responders Based on Target Joint Pain Score at 24 Hours Post First Dose</content>
                  </paragraph>
                  <table width="100%" cellspacing="0" cellpadding="0" border="1">
                     <col width="1pt1ptmedium"/>
                     <col width="1pt1ptmedium"/>
                     <col width="1pt1ptmedium"/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Colchicine Dose </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Responders n (%) </content>
                              </paragraph>
                           </td>
                           <td rowspan="2">
                              <paragraph>
                                 <content styleCode="bold">Placebo </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">n (%) </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(n=58)</content>
                              </paragraph>
                           </td>
                           <td colspan="2">
                              <paragraph>
                                 <content styleCode="bold">% Differences in Proportion </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Low-Dose </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(n=74)</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">High-Dose</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(n=52)</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">Low-Dose vs Placebo (95% CI)</content>
                              </paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">High-Dose vs Placebo (95% CI)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>28 (38%) </paragraph>
                           </td>
                           <td>
                              <paragraph>17 (33%)</paragraph>
                           </td>
                           <td>
                              <paragraph>9 (16%)</paragraph>
                           </td>
                           <td>
                              <paragraph>22 (8, 37) </paragraph>
                           </td>
                           <td>
                              <paragraph>17 (1, 33)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="italics">Figure 1</content> shows the percentage of patients achieving varying degrees of improvement in pain from baseline at 24 hours.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1 Pain Relief on Low and High Doses of Colchicine and Placebo (Cumulative)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM2"/>
                     </content>
                  </paragraph>
                  <paragraph>The evidence for the efficacy of colchicine in patients with FMF is derived from the published literature. Three randomized, placebo-controlled studies were identified. The three placebo-controlled studies randomized a total of 48 adult patients diagnosed with FMF and reported similar efficacy endpoints as well as inclusion and exclusion criteria. </paragraph>
                  <paragraph>One of the studies randomized 15 patients with FMF to a six month crossover study during which five patients discontinued due to study noncompliance. The ten patients completing the study experienced five attacks over the course of 90 days while treated with colchicine compared to 59 attacks over the course of 90 days while treated with placebo. Similarly, the second study randomized 22 patients with FMF to a four month crossover study during which nine patients discontinued due to lack of efficacy while receiving placebo or study noncompliance. The 13 patients completing the study experienced 18 attacks over the course of 60 days while treated with colchicine compared to 68 attacks over the course of 60 days while treated with placebo. The third study was discontinued after an interim analysis of six of the 11 patients enrolled had completed the study; results could not be confirmed. </paragraph>
                  <paragraph>Open-label experience with colchicine in adults and children with FMF is consistent with the randomized, controlled trial experience and was utilized to support information on the safety profile of colchicine and for dosing recommendations. </paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="colchicine-tablets-usp-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f76f8b37-9c67-4577-8ffb-8a348f8796b7">
               <id root="6e991a22-1ff8-4f25-984e-12ea2b40ecbe"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16Â  HOW SUPPLIED/STORAGE AND HANDLING 
</content>
               </title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="LINK_634291e8-942a-4e41-9cfa-931bda3659ee">
                     <id root="d9463d7a-91d2-4779-b22e-10864816b85b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Colchicine tablets, USP, <content styleCode="bold">0.6 mg,</content> are purple, capsule-shaped, film-coated tablets, scored on one side and debossed with âA10â on the other side.</paragraph>
                        <paragraph>They are available as:</paragraph>
                        <paragraph>Bottles of 30:Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 65162-710-03<br/>Bottles of 90:Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 65162-710-09<br/>Bottles of 1,000:Â Â Â Â Â Â Â Â  NDC 65162-710-11</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_abf33f34-edc2-4279-bf80-0e28abb1a859">
                     <id root="64e12583-d129-4e5a-8b68-e8f088b84811"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.2 Storage</title>
                     <text>
                        <paragraph>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph>Protect from light.</paragraph>
                        <paragraph>DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a958d3f2-3d34-4830-8d5a-62a548191220">
               <id root="1380b94a-f5b0-41ce-81cb-82252b1d178c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17Â  PATIENT COUNSELING INFORMATION </content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosing Instructions </content>
                  </paragraph>
                  <paragraph>Patients should be advised to take colchicine as prescribed, even if they are feeling better. Patients should not alter the dose or discontinue treatment without consulting with their doctor. If a dose of colchicine is missed:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>For treatment of a gout flare when the patient is not being dosed for prophylaxis, take the missed dose as soon as possible. </item>
                     <item>For treatment of a gout flare during prophylaxis, take the missed dose immediately, wait 12 hours, then resume the previous dosing schedule. </item>
                  </list>
                  <list listType="unordered" styleCode="Disc">
                     <item>For prophylaxis without treatment for a gout flare, or FMF, take the dose as soon as possible and then return to the normal dosing schedule. However, if a dose is skipped the patient should not double the next dose. </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Fatal Overdose </content>
                  </paragraph>
                  <paragraph>Instruct patient that fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine. Colchicine should be kept out of the reach of children. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Blood Dyscrasias </content>
                  </paragraph>
                  <paragraph>Patients should be informed that bone marrow depression with agranulocytosis, aplastic anemia and thrombocytopenia may occur with colchicine. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug and Food Interactions </content>
                  </paragraph>
                  <paragraph>Patients should be advised that many drugs or other substances may interact with colchicine and some interactions could be fatal. Therefore, patients should report to their healthcare provider all of the current medications they are taking and check with their healthcare provider before starting any new medications, particularly antibiotics. Patients should also be advised to report the use of nonprescription medication or herbal products. Grapefruit and grapefruit juice may also interact and should not be consumed during colchicine treatment. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Neuromuscular Toxicity </content>
                  </paragraph>
                  <paragraph>Patients should be informed that muscle pain or weakness, tingling or numbness in fingers or toes may occur with colchicine alone or when it is used with certain other drugs. Patients developing any of these signs or symptoms must discontinue colchicine and seek medical evaluation immediately. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility </content>
                  </paragraph>
                  <paragraph>Advise males of reproductive potential that colchicine may rarely and transiently impair fertility <content styleCode="italics">[see <linkHtml href="#www.splportal.comLINK_4850c610-a169-449f-9355-21fb173ac103">Use in Specific Populations (8.3)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>Distributed by: <br/>
                     <content styleCode="bold">Amneal Pharmaceuticals LLC<br/>
                     </content>Bridgewater, NJ 08807</paragraph>
                  <paragraph>Rev. 03-2025-05</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4d7ab666-0b63-4249-92ca-aa3e8088dc27">
               <id root="b7d0cf00-956a-4b7a-993b-90663362c251"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>
                  <content styleCode="bold">MEDICATION GUIDE</content>
               </title>
               <text>
                  <table width="100%">
                     <col width="17pt"/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">Colchicine (kolâ chi seen) Tablets, USP for oral use</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â Read the Medication Guide that comes with colchicine tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about colchicine tablets when you start taking it and at regular checkups. </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information that I should know about colchicine tablets? </content>
                              </paragraph>
                              <paragraph>Colchicine tablets can cause serious side effects or death if levels of colchicine are too high in your body. </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Taking certain medicines with colchicine tablets can cause your level of colchicine to be too high, especially if you have kidney or liver problems. </item>
                                 <item>Tell your healthcare provider about all your medical conditions, including if you have kidney or liver problems. Your dose of colchicine tablets may need to be changed. </item>
                                 <item>Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements. </item>
                                 <item>Even medicines that you take for a short period of time, such as antibiotics, can interact with colchicine tablets and cause serious side effects or death. </item>
                                 <item>Talk to your healthcare provider or pharmacist before taking any new medicine. </item>
                                 <item>Especially tell your healthcare provider if you take: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>atazanavir sulfate (Reyataz) </item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>clarithromycin (Biaxin)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>cyclosporine (Neoral, Gengraf, Sandimmune)</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>darunavir (Prezista)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>fosamprenavir (Lexiva) with ritonavir</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>fosamprenavir (Lexiva)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>indinavir (Crixivan)</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>itraconazole (Sporanox)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>ketoconazole (Nizoral)</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>lopinavir/ritonavir (Kaletra)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>nefazodone (Serzone)</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>nelfinavir mesylate (Viracept)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>ritonavir (Norvir)</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>saquinavir mesylate (Invirase)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>telithromycin (Ketek)</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">Â 
            <list listType="unordered" styleCode="Circle">
                                 <item>tipranavir (Aptivus)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Ask your healthcare provider or pharmacist if you are not sure if you take any of the medicines listed above. This is not a complete list of all the medicines that can interact with colchicine tablets.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</item>
                                 <item>Keep colchicine tablets out of the reach of children. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are colchicine tablets? </content>
                              </paragraph>
                              <paragraph>Colchicine tablets are a prescription medicine used to: </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>prevent and treat gout flares in adults</item>
                                 <item>treat familial Mediterranean fever (FMF) in adults and children age 4 or older </item>
                              </list>
                              <paragraph>Colchicine tablets are not a pain medicine, and it should not be taken to treat pain related to other conditions unless specifically prescribed for those conditions. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Who should not take colchicine tablets? </content>
                              </paragraph>
                              <paragraph>Do not take colchicine tablets if you have liver or kidney problems and you take certain other medicines. Serious side effects, including death, have been reported in these patients even when taken as directed. See <content styleCode="bold">
                                    <content styleCode="bold">âWhat is the most important information that I should know about colchicine tablets?â</content>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What should I tell my healthcare provider before starting colchicine tablets? </content>
                              </paragraph>
                              <paragraph>See <content styleCode="bold">âWhat is the most important information that I should know about colchicine tablets?â </content>
                              </paragraph>
                              <paragraph>Before you take colchicine tablets, tell your healthcare provider about all your medical conditions, including if you: </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have liver or kidney problems. </item>
                                 <item>are pregnant or plan to become pregnant. It is not known if colchicine tablets will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.</item>
                                 <item>are a <content styleCode="bold">male </content>with a female partner who can become pregnant. Receiving treatment with colchicine tablets may be related to infertility in some men that is reversible when treatment is stopped.</item>
                                 <item>are breastfeeding or plan to breastfeed. Colchicine passes into your breast milk. You and your healthcare provider should decide if you will take colchicine tablets while breastfeeding. If you take colchicine tablets and breastfeed, you should talk to your childâs healthcare provider about how to watch for side effects in your child. </item>
                              </list>
                              <paragraph>Tell your healthcare provider about all the medicines you take, including ones that you may only be taking for a short time, such as antibiotics. See <content styleCode="bold">âWhat is the most important information that I should know about colchicine tablets?â</content> Do not start a new medicine without talking to your healthcare provider.<br/>
                                 <br/>
            Using colchicine tablets with certain other medicines, such as cholesterol-lowering medications and digoxin, can affect each other, causing serious side effects. Your healthcare provider may need to change your dose of colchicine tablets. Talk to your healthcare provider about whether the medications you are taking might interact with colchicine tablets and what side effects to look for. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I take colchicine tablets?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take colchicine tablets exactly as your healthcare provider tells you to take it. <content styleCode="bold">If you are not sure about your dosing</content>, call your healthcare provider. </item>
                                 <item>Colchicine tablets can be taken with or without food. </item>
                                 <item>If you take too much colchicine tablets, go to the nearest hospital emergency room right away. </item>
                                 <item>Do not stop taking colchicine tablets even if you start to feel better, unless your healthcare provider tells you. </item>
                                 <item>Your healthcare provider may do blood tests while you take colchicine tablets. </item>
                                 <item>If you take colchicine tablets daily and you miss a dose, then take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. Do not take 2 doses at the same time. </item>
                                 <item>If you have a gout flare while taking colchicine tablets daily, report this to your healthcare provider.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid while taking colchicine tablets? </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Avoid eating grapefruit or drinking grapefruit juice while taking colchicine tablets. It can increase your chances of getting serious side effects. </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of colchicine tablets? </content>
                              </paragraph>
                              <paragraph>Colchicine tablets can cause serious side effects or even cause death. See <content styleCode="bold">âWhat is the most important information that I should know about colchicine tablets?â </content>
                              </paragraph>
                              <paragraph>Get medical help right away if you have: </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Muscle weakness or pain </item>
                                 <item>Numbness or tingling in your fingers or toes </item>
                                 <item>Unusual bleeding or bruising </item>
                                 <item>Increased infections </item>
                                 <item>Feel weak or tired </item>
                                 <item>Pale or gray color to your lips, tongue or palms of your hands </item>
                                 <item>Severe diarrhea or vomiting </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Gout Flares: </content>The most common side effect of colchicine tablets in people who have gout flares is diarrhea.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">FMF:</content> The most common side effects of colchicine tablets in people who have FMF are abdominal pain, diarrhea, nausea and vomiting. </paragraph>
                              <paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </paragraph>
                              <paragraph>These are not all of the possible side effects of colchicine tablets. For more information, ask your healthcare provider or pharmacist. </paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store colchicine tablets? </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store colchicine tablets at room temperature between 68Â°F and 77Â°F (20Â°C to 25Â°C). </item>
                                 <item>Keep colchicine tablets in a tightly closed container. </item>
                                 <item>Keep colchicine tablets out of the light. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep colchicine tablets </content>
                                 <content styleCode="bold">and all medicines out of the reach of children. </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General Information about Colchicine Tablets</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use colchicine tablets for a condition for which it was not prescribed. Do not give colchicine tablets to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about colchicine tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about colchicine tablets that is written for healthcare professionals. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in colchicine tablets? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active Ingredient:</content> colchicine </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive Ingredients:</content> ethanol, FD&amp;C blue #2, FD&amp;C red #40, hypromellose, lactose monohydrate, macrogol, magnesium stearate, microcrystalline cellulose, polydextrose,Â  pregelatinized starch (corn), purified water, sodium starch glycolate, titanium dioxide and triacetin.<br/>
                                 <br/>
            Distributed by:<br/>
                                 <content styleCode="bold">Amneal Pharmaceuticals LLC<br/>
                                 </content>Bridgewater, NJ 08807</paragraph>
                              <paragraph>Rev. 03-2025-05<br/>
                                 <br/>
            Trademarks are the property of their respective owners.</paragraph>
                              <paragraph> For more information, go to www.amneal.com or call 1-877-835-5472.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="LINK_190cf513-e157-47b9-91d1-0fc7ffd43810">
               <id root="feff4c07-c48a-4f6b-82f2-c7efca747472"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 65162-710-11<br/>Colchicine tablets, USP, 0.6 mg<br/>1000 Count Container Label<br/>Rx only<br/>Amneal Pharmaceuticals LLC</content>
                     <br/>
                     <renderMultiMedia referencedObject="MM3"/>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="colchicine-tablets-usp-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>